Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / February 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
Jim Cramer on Elanco Animal Health Incorporated (ELAN): ‘Not My Favorite’
We recently published an article titled Jim Cramer Looked Closely At These 10 Stocks. In this article, we are going to take a ...
CSR Wire5d
Meet the Faces of Zen: Elanco’s Zenrelia™ (ilunocitinib tablets) Helps Allergic Dogs Get Back to Normal
Newly published study in a leading peer-reviewed, international journal, Veterinary Dermatology, compares clinical outcomes between Zenrelia and Apoquel® (oclacitinib tablet) ...
Hosted on MSN7d
Elanco price target lowered to $14 from $15 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Elanco (ELAN) to $14 from $15 and keeps an Equal Weight rating on the shares. After having met ...
Business Insider6d
Bronstein, Gewirtz & Grossman, LLC Encourages Elanco Animal Health Incorporated (ELAN) Investors to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased ...
Yahoo Finance6d
Meet the Faces of Zen: Elanco's Zenrelia(TM) (ilunocitinib tablets) Helps Allergic Dogs Get Back to Normal
In fact, a newly published study in a leading peer-reviewed, international journal, Veterinary Dermatology, described the findings of a randomized, clinical trial which compared Zenrelia to the ...